Loading
Loading
Advanced / Specialty Compounds · 750mcg
Janoshik-tested · 10 vials per kit
Teriparatide is a synthetic analog of parathyroid hormone PTH(1-34) studied in preclinical and clinical research for its bone metabolism effects. Research has examined its potential to stimulate bone matrix synthesis and mineralization, enhance bone mineral density, improve bone microarchitecture, regulate calcium and phosphorus metabolism, and increase intestinal calcium absorption. Studies have explored applications in severe osteoporosis and high fracture-risk models.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Teriparatide
Forteo — PTH(1-34)
Teriparatide (Forteo) is a synthetic 34-amino-acid N-terminal fragment of human parathyroid hormone (PTH 1-34), representing the biologically active portion of the 84-amino-acid PTH molecule. FDA-approved since 2002 for osteoporosis in postmenopausal women and men at high fracture risk, it was the first anabolic (bone-building) agent approved for osteoporosis — all prior therapies were anti-resorptive.
Teriparatide activates PTH1R (parathyroid hormone 1 receptor) on osteoblasts, osteocytes, and bone marrow stromal cells. When administered as an intermittent once-daily subcutaneous injection, transient PTH1R activation stimulates net bone formation through: inhibition of osteoblast apoptosis (extending the active lifespan of bone-building cells), increased osteoblast proliferation and differentiation from stromal precursors, and upregulation of Wnt/β-catenin and IGF-1 signalling. This intermittent anabolic effect contrasts with continuous PTH exposure (as in primary hyperparathyroidism), which favours bone resorption.
Osteoporosis (spine BMD increases of 8-10%, hip 3% in Phase 3 trials), fracture risk reduction (vertebral fractures reduced ~65%, non-vertebral ~53%), stress fracture healing, spinal fusion enhancement, bone regeneration after avascular necrosis, and combination/sequential strategies with anti-resorptive agents (denosumab or bisphosphonates after completing the anabolic course maximise the gained bone density).
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
